BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission has asked the Committee for Medicinal Products for Human Use (CHMP) to consider two ...

The U.S. Food and Drug Administration approved Eisai and Biogen’s application for IV maintenance dosing of lecanemab on January 27. Previously, the label called for biweekly IV dosing. The new ...

What about pharma? Imposing tariffs on imported pharmaceuticals could weigh on Japan, home of major drugmakers such as Takeda ...

This health briefing covers a range of current issues: attacks on healthcare in Sudan, COVID-19's origins, drug breakthroughs ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment   TOKYO and CAMBRIDGE, Mass., Jan. 26, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: ...

Indian drugmaker Alivus Life Sciences , formerly called Glenmark Life Sciences, reported a higher third-quarter profit on Thursday, driven by strong demand in its mainstay active pharmaceutical ...

U.S. President Donald Trump plans to impose tariffs on imported computer chips, pharmaceuticals and steel, he said on Monday, ...

The Global Oncology Drug market was estimated at $227.2 billion in 2024 and is projected to reach $582.21 billion by 2034 , reflecting a robust CAGR of 11.67% over the forecast period from 2024 to ...

Japan’s market growth accelerates through dynamic clinical partnerships, biologic breakthroughs, and automated facilities. Japanese firms confront shifting priorities in specialized therapies, ...

US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug Future ... of 11 products made at the drugmaker's facility in India after the regulator's inspection found it had violated ...